Combined immunotherapy with whole tumor lysate–pulsed interleukin-15–activated dendritic cells and cucurbitacin I promotes strong CD8+ T-cell responses and …
Background aims Dendritic cell (DC)-based therapies could be important strategies for
lymphoma treatment. Methods AKR/J mice with Dalton's lymphoma were treated with
recombinant interleukin-15 (rIL-15)-activated autologous DCs and pulsed with whole tumor
cell lysates in the presence or absence of suboptimal doses of the STAT3 inhibitor
cucurbitacin I. One group of treated mice received an additional dose of rIL-15 to boost the
DC-based adoptive cell therapy (ACT). Kaplan-Meier survival analysis and multiple …
lymphoma treatment. Methods AKR/J mice with Dalton's lymphoma were treated with
recombinant interleukin-15 (rIL-15)-activated autologous DCs and pulsed with whole tumor
cell lysates in the presence or absence of suboptimal doses of the STAT3 inhibitor
cucurbitacin I. One group of treated mice received an additional dose of rIL-15 to boost the
DC-based adoptive cell therapy (ACT). Kaplan-Meier survival analysis and multiple …